Thus, it was of interest that our recent discovery demonstrated that STK11 mutant NSCLCs treated with AXL inhibitors (targeting AXL in the tumor microenvironment dendritic cells) can now respond to immune checkpoint blockade therapy (19). This evidence concerns the gene STK11 and neoplasm.